Summary & Overview
CPT 88307: Surgical Pathology, Level V Tissue Examination
CPT code 88307 is a pivotal billing code for Level V surgical pathology, encompassing both gross and microscopic examination of tissue specimens. This procedure is integral to the diagnosis and management of complex medical conditions, including malignancies and other significant tissue abnormalities. Nationally, the code is recognized by major payers such as Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad coverage for pathology services across diverse healthcare settings.
This publication provides a comprehensive overview of 88307, including its clinical context, typical laboratory site of service, and its role in surgical pathology. Readers will gain insight into relevant benchmarks, policy updates, and the importance of accurate coding for pathology procedures. The analysis also highlights associated modifiers, taxonomies, and common ICD-10 diagnoses linked to this code, offering a clear understanding of its application in medical billing and compliance. Additionally, related CPT codes are discussed to illustrate the spectrum of surgical pathology services. The information presented is designed to support healthcare professionals, administrators, and policy analysts in navigating the complexities of pathology billing and reimbursement.
CPT Code Overview
CPT code 88307 represents Level V surgical pathology, gross and microscopic examination. This procedure involves the detailed evaluation of tissue specimens removed during surgery, utilizing both gross and microscopic techniques to provide critical diagnostic information. The service type is Pathology, and it is typically performed in a laboratory setting (Place of Service 81). This code is essential for identifying and characterizing complex disease processes, guiding clinical management, and informing treatment decisions.
Clinical & Coding Specifications
Clinical Context
A patient presents with a suspicious mass in the colon identified during a routine colonoscopy. The gastroenterologist performs a surgical resection of the affected segment. The specimen is sent to the laboratory (Place of Service 81) for a Level V surgical pathology examination. The pathologist performs both gross and microscopic evaluation to determine the nature of the lesion, such as confirming malignancy or identifying a polyp. This workflow is typical for cases involving suspected malignant neoplasms or polyps of the colon, breast, or other tissues, as indicated by the associated ICD-10 diagnoses.
Coding Specifications
-
Modifiers:
26: Professional Component – Used when only the pathologist's interpretation and report are billed, not the laboratory technical work.TC: Technical Component – Used when only the laboratory's technical work (preparation, staining, etc.) is billed, not the physician's interpretation.59: Distinct Procedural Service – Used to indicate that a procedure or service is distinct or independent from other services performed on the same day.91: Repeat Clinical Diagnostic Laboratory Test – Used when the same laboratory test is repeated on the same patient on the same day.
-
Provider Taxonomies:
Code Specialty Name 207ZP0102XAnatomic Pathology & Clinical Pathology 207ZP0101XCytopathology 207ZP0105XSurgical Pathology
These taxonomies represent providers specializing in pathology, including surgical pathology, cytopathology, and anatomic/clinical pathology.
Related Diagnoses
-
C50.911: Malignant neoplasm of unspecified site of right female breast- Relevant for cases where breast tissue is resected and examined for malignancy.
-
C18.9: Malignant neoplasm of colon, unspecified- Used when colon tissue is resected to evaluate for cancer.
-
D49.2: Neoplasm of unspecified behavior of bone, soft tissue, and skin- Applied when the behavior of a neoplasm is unclear and requires detailed pathology examination.
-
N63: Unspecified lump in breast- Used for cases where a breast lump is excised and sent for pathology to determine its nature.
-
K63.5: Polyp of colon- Relevant for colon specimens removed to assess for benign or malignant polyps.
Each diagnosis code represents a clinical scenario where a surgical specimen is submitted for Level V gross and microscopic pathology examination as described by 88307.
Related CPT Codes
-
88305: Level IV - Surgical pathology, gross and microscopic examination- Used for specimens requiring less complex evaluation than
88307. May be used as an alternative for less involved cases.
- Used for specimens requiring less complex evaluation than
-
88309: Level VI - Surgical pathology, gross and microscopic examination- Used for specimens requiring more extensive evaluation than
88307. May be used as an alternative for highly complex cases.
- Used for specimens requiring more extensive evaluation than
-
88342: Immunohistochemistry or immunocytochemistry, per specimen- Often used in conjunction with
88307when additional immunostaining is required to further characterize the tissue.
- Often used in conjunction with
-
88341: Immunohistochemistry or immunocytochemistry, each additional single antibody stain procedure- Used alongside
88342for each additional antibody stain needed. Commonly billed together when multiple stains are performed.
- Used alongside
88305, 88307, and 88309 are alternatives based on specimen complexity, while 88342 and 88341 are commonly used together with 88307 for advanced tissue analysis.
National Reimbursement Benchmarks
For CPT code 88307, the national mean rate for Medicare is $193.27, while the BUCA (average commercial) mean rate is $195.00. This places Medicare's average reimbursement close to the commercial benchmark, with both rates falling below the highest mean rates observed for Aetna ($218.85) and Blue Cross Blue Shield ($216.42).
Rate dispersion, measured as the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna exhibits the widest spread ($154.33), indicating greater variability in contracted rates. In contrast, UnitedHealth Group shows the tightest range ($91.33), suggesting more consistent rates nationally. Aetna, Blue Cross Blue Shield, and Medicare all display moderate dispersion, with ranges between $99.71 and $188.00.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
State Benchmarks
State: AK1 / 51
Alaska Benchmarks
Alaska's reimbursement rates for CPT code 88307 show a substantial spread between payers. The rate spread, calculated as the difference between the 75th and 25th percentiles, is most pronounced for Aetna ($764.00 - $716.50 = $47.50) and Blue Cross Blue Shield ($747.00 - $443.03 = $303.97), indicating significant variability in payment levels. Cigna Health and Medicare have much narrower spreads, suggesting more consistent rates across providers. Compared to national averages, Alaska's commercial payers, especially Aetna and Blue Cross Blue Shield, offer considerably higher mean rates, with Aetna's mean rate in Alaska ($678.05) far exceeding its national mean ($218.85).
The table and chart below present the full breakdown of mean rates and percentile values for each major payer in Alaska, highlighting the differences in reimbursement levels and the relative position of each payer within the state.
Key Insights for Alaska
- Aetna is the highest paying payer for CPT 88307 in Alaska, with a mean rate of $678.05.
- Medicare and Cigna Health are the lowest paying payers, with mean rates of $185.72 and $191.90, respectively.
- All major commercial payers in Alaska reimburse at rates significantly above their national averages, with Aetna's mean rate more than triple the national mean.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.